Zostovax was approved by the FDA in May, 2006. The FDA recommended it only for adults aged 60 who meet the following requirements:
On October 25th, 2006, the CDC's Advisory Committee on Immunization Practices (ACIP) voted to recommend that Zostavax be given to all adults age 60 and over, including those who have had a previous episode of shingles.
In Investigational Study, ZOSTAVAX[R], Merck's Shingles Vaccine, Reduced Incidence of Shingles in Adults Ages 50 to 59 by Nearly 70 Percent.(Clinical report)
Nov 03, 2010; In a large clinical study of adults ages 50 to 59, Zostavax[R] (Zoster Vaccine Live), Merck's vaccine for the prevention...
ADDING and REPLACING FDA Expands Indication for ZOSTAVAX[R], Merck's Shingles Vaccine, to Include Adults Ages 50 to 59.
Apr 13, 2011; Re-issuing release dated March 24, 2011 with updated prescribing information (see also Chicken Pox). The re-issued release reads:...